Neoplasms

All Conditions

Rare Diseases

Medulloblastoma

Neuroblastoma

Rhabdoid Tumor

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neuroectodermal Tumors, Primitive, Peripheral

Neoplasms, Neuroepithelial

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Glioma

Embryonal Tumor With Multilayered Rosettes

Neuroepithelioma

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Eflornithine

Antiprotozoal Agents

Antiparasitic Agents

Enzyme Inhibitors

Ornithine

In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID

Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS.

eflornithine HCl

Genevieve Bergendahl, MSN

Suzanne Treadway

Valerie Brown, MD

Giselle Sholler, MD

To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
An Intermediate Expanded Use Trial of DFMO	NCT03581240	Neuroblastoma Medulloblastoma Typical Teratoi... Embryonal Tumor... Ependymoblastom... Medulloepitheli...	eflornithine HC...	0 Years - 30 Years	Milton S. Hershey Medical Center
An Intermediate Expanded Use Trial of DFMO	NCT03581240	Neuroblastoma Medulloblastoma Typical Teratoi... Embryonal Tumor... Ependymoblastom... Medulloepitheli...	eflornithine HC...	0 Years - 30 Years	Milton S. Hershey Medical Center

Spots Global Cancer Trial Database for typical teratoid rhabdoid tumor